Cheng and Lama et al. developed a synergistic dual-modality AI framework for prediction of MMRd/MSI-High status in colorectal cancer and PD-L1 status in breast cancer. Their model, which analyzes H&E and IHC images, achieves clinical grade performance and identifies patients with improved outcomes on pembrolizumab immunotherapy.
- Yating Cheng
- Norsang Lama
- George W. Sledge
